Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal dose

Bone Marrow Transplantation volume 49, pages 1239–1240 (2014)Cite this article

Subjects

Autologous hematopoietic SCT (auto-HSCT) is widely employed as consolidation therapy in aggressive Non-Hodgkin lymphoma (NHL) and relapsed or refractory classic Hodgkin's lymphoma. However, there is no evidence regarding the best conditioning regimen to be used. New schemes have therefore been proposed to reduce the toxicity, costs related to the procedure and hospitalization time, without compromising the quality of life and survival of patients.1 The maximum recommended dose of lomustine (CCNU) associated with etoposide and cyclophosphamide has been 600 mg/m2.2,3 However, when it is associated with a combination of etoposide, ara-C and cyclophosphamide, or etoposide, ara-C and melphalan, a dose of 200 mg/m2 has been used.4, 5, 6

Although the success of auto-HSCT depends on several variables, the lower the toxicity and the duration of neutropenia the smaller the treatment-related mortality.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011; 118: 3419–3425.

    Article  CAS  PubMed  Google Scholar 

  2. Chao NJ, Kastrissios H, Long GD, Negrin RS, Homing SJ, Wong RM et al. A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. Cancer 1995; 75: 1354–1359.

    Article  CAS  PubMed  Google Scholar 

  3. Stuart MJ, Chao NS, Horning SJ, Wong RM, Negrin RS, Johnston LJ et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory hodgkin’s disease. Biol Blood Marrow Transplant 2001; 7: 552–560.

    Article  CAS  PubMed  Google Scholar 

  4. Perz JB, Giles C, Szydlo R, O’Shea D, Sanz J, Chaidos A et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin’s lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant 2007; 39: 41–47.

    Article  CAS  PubMed  Google Scholar 

  5. Ramzi M, Mohamadian M, Vojdani R, Dehghani M, Nourani H, Zakerinia M, Haghighinejad H . Autologous noncryopreserved hematopoietic stem cell transplant With CEAM as a modified conditioning regimen in patients with hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant 2012; 10: 163–167.

    Article  PubMed  Google Scholar 

  6. Hallack Neto AE, Santos KB, Atalla A . Modified BEAM conditioning regimen in patients with Hodgkin and Non-Hodgkin lymphomas. Exp Clin Transplant 2012; 10: 622.

    Article  PubMed  Google Scholar 

  7. Santos KB, Hallack Neto AE, Silva GA, Atalla A, Abreu MM, Ribeiro LC . Infection profile of patients undergoing autologous bone marrow transplantation in a Brazilian institution. Sao Paulo Med J 2012; 130: 10–16.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Bone Marrow Transplantation, Minas Gerais, Universidade Federal de Juiz de Fora, Brazil,

    K B dos Santos

  2. Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, USA,

    L J Costa

  3. Division of Clinical Medical, Universidade Federal de Juiz de Fora, Minas Gerais, Brazil,

    A Atalla & A E Hallack-Neto

  4. Division of Hematology, Universidade Federal de São Paulo, São Paulo, Brazil,

    J Pereira

Authors
  1. K B dos Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L J Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Atalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A E Hallack-Neto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A E Hallack-Neto.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

dos Santos, K., Costa, L., Atalla, A. et al. Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal dose. Bone Marrow Transplant 49, 1239–1240 (2014). https://doi.org/10.1038/bmt.2014.121

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.121

This article is cited by

Search

Advanced search

Quick links